Post by Kyowa Kirin International plc.

Grateful to the FDA for selecting our Sanford, NC manufacturing facility for the FDA PreCheck Pilot program. This program will enable us to accelerate production timelines and strengthen supply chain resilience for patients across the U.S. The facility, which broke ground in late 2024 and is on track to be operational by 2027, will serve as a core domestic hub for manufacturing innovative biologic therapies, with a heavy emphasis on next-generation antibodies for rare and orphan diseases. Learn more here: https://lnkd.in/ewtMDSBP